The ratio of pro -apoptotic ( PAP ) and anti -apoptotic ( AAP ) bcl -2 proteins is important in apoptosis regulation. We sought to determine if inhibition of the AAP bcl -xl by sodium butyrate ( SB ) would augment apoptotic cellular death in mesothelioma when combined with adenoviral pro -apoptotic gene therapy ( PAGT ) by simultaneously increasing PAP and decreasing AAP in these cells. Human mesothelioma cell lines were exposed to AdBax, AdBak, Adp53, and SB alone as well as all vectors combined with SB at varying doses and time points. Cell death was assessed, and apoptosis evaluated by morphology and FACS. Isobologram analysis evaluated additive or synergistic effect. Cellular death and apoptosis were augmented by PAGT / SB combinations compared to monotherapy. Following AdBax / SB and AdBak / SB, a decrease of the AAP bcl -xl was noted in combination with increases in PAP bax and bak. By isobologram analysis, additive or synergistic cell killing was noted with both combinations. SB treatment did not significantly augment cell killing or apoptosis in combination with Adp53. PAGT / SB was more effective than monotherapy in induction of apoptotic cell death. Synergy may be due to the ability of SB to decrease bcl -xl with marked increases in PAP engendered by PAGT. Combination therapy with agents that down -regulate AAP in addition to PAGT may prove useful clinically.
M alignant pleural mesothelioma (MPM ) is a tumor originating from the lining of the pleural space and surface of the lung ( visceral and parietal pleura ). Although less common than other thoracic malignancies, such as nonsmall cell lung carcinoma, this tumor continues to be a difficult clinical problem with a high case:fatality ratio. Advances in staging and evaluation have identified a select subgroup that may benefit from aggressive multimodality therapy, but the prognosis for all presenting with this disease remains poor with a median survival of 12-18 months. 1, 2 This tumor is clinically resistant to conventional chemotherapeutic agents, with no regimen consistently demonstrating response rates of greater than 20%, and the majority of all clinical chemotherapy trials without significant benefit. 3 -5 This failure of conventional treatment has led to an interest in novel approaches, such as prodrug gene therapy, using the herpes simplex virus thymidine kinase/ ganciclovir system and immunotherapy. 6 -8 Another novel approach being explored in cancer treatment, although little studied in mesothelioma, is the forced induction of programmed cell death or apoptosis. The bcl -2 gene family has long been known to play a major role in the apoptotic pathway. 9 By altering the ratio of expression of various bcl -2 family genes in cells [ anti -apoptotic proteins (AAP ):proapoptotic proteins ( PAP )], apoptosis can either be induced or inhibited.
Sodium butyrate ( SB ) is a byproduct of dietary fiber degradation that is thought to be important for the maintenance of a healthy gut epithelium. 10 Its physiologic effects are diverse. In vitro butyrate exposure has been shown to cause reversible growth arrest, differentiation, apoptosis, and death in a variety of solid tumor cell lines ( colon, hepatic, breast, and others). 11 -13 The reported mechanisms for these effects have varied considerably, and include down -regulation of BCL -2 and BCL -XL expression, 13, 14 fas -fas -ligand interactions, 15 caspase activation, 16 and others. Nontoxic in vivo intravenous and oral use of SB in rodents and dogs has been reported, as well as intravenous use in human leukemia patients. 17, 18 In earlier studies, we have demonstrated that when treated with SB, human mesothelioma cell lines undergo apoptotic cell death with a concomitant significant decrease in bcl -xl protein expression, with no effect on the production of bax or bak protein ( manuscript submitted ). Expression of the bcl -xl gene in mesothelioma (in regard to maintenance of apoptotic homeostasis ) may be more important than in many other tumor types, due to the fact that expression of another major AAP, bcl -2, is uncommon in mesothelioma tumor specimens and cell lines. 19, 20 A recombinant binary adenoviral vector system, which can transduce human cells with the PAP bax and bak genes with subsequent PAP expression, has been developed. This novel gene therapy system has been successful in inducing apoptosis in both nonsmall cell carcinoma as well as mesothelioma cells in vitro. 21 -23 In addition, adenoviral transfer of the p53 gene has been extensively studied, both in preclinical and now in clinical settings. 24 A theoretical ''forced therapeutic imbalance'' of PAP and AAP can therefore be envisioned with treatment of cells with an agent capable of down -regulating AAP gene expression in combination with transfer and marked overexpression of a PAP by recombinant adenovirus. The purpose of our study was to assess the effects of combination therapy with the PAP adenoviral vectors AdBax, AdBak, and Adp53 plus SB on mesothelioma cell lines. We demonstrate that although individually these agents are effective in inducing apoptosis and cellular death, in combination, these effects are augmented significantly.
MATERIALS AND METHODS

Cell lines, culture conditions, and growth
All cells were maintained in RPMI media supplemented with 10% fetal bovine serum and 100 g /mL of streptomycin ( Life Technologies, Grand Island, NY ) in an atmosphere of 5% CO 2 at 378C. Both REN and I-45 are human mesothelioma cell lines that were originally derived from patients with pleural tumors. The REN (inflammatory epithelial subtype, p53 mutant ) cell line was developed by the primary author (W.R.S. ) and has been previously described. 25 The I -45 (sarcomatous subtype, p53 wild type ) cell line was originally provided by Dr. Joe Testa of the Fox Chase Cancer Center in Philadelphia, PA.
Adenoviral pro -apoptotic gene therapy ( PAGT ) vectors
Construction of the AdLacZ, Ad / GV16, AdBak, AdBax, and Adp53 vectors has been previously described. 22 -24 The development of a binary adenoviral vector system was required for AdBak and AdBax due to producer cell toxicity. The system consisted of coadministration of AdBak or AdBax +Ad /GV16 (hereafter described as AdBak and AdBax ) or Ad / GT-LacZ + Ad /GV16 (hereafter described as AdLacZ ). The transduction efficiencies of the cell lines were determined with Ad /GT-LacZ + Ad /GV16. Cells were transfected in 96 -well plates, chamber slides, and 10 -ml dishes. Cells were initially harvested, counted, and then incubated overnight. Cells were then washed with phosphate -buffered saline ( PBS ) and transfected with increasing viral particles of vectors using the binary system as described previously in serum -free media. The Adp53 vector has been described earlier, and does not require a binary transduction system (REFS ). After 4 hours of exposure to virus, 20% media supplemented with fetal bovine serum was then added in equal volumes to bring the final concentration to 10%.
Butyrate treatment
SB (molecular weight 110.09 ) ( Sigma Chemical, St. Louis, MO ) was prepared by dissolving in sterile PBS solution with pH of 7.2. The solution was prepared fresh for each experiment, or frozen and used following no more than two freeze -thaw cycles.
Transfection efficiency
Mesothelioma cells were plated at concentrations of 1 million cells per plate in 6 -cm plates. After a 24-hour incubation period, cells were treated with either 2.5 mM SB or PBS. Following an incubation period of 24 hours, all cells were transfected with Ad -GFP (adenovirus -transducing cells with green fluorescent protein ) at multiplicity of infection ( MOI ) of 10 and 20. The following day, cells were read using an Epics flow cytometer. Cells were gated for GFP. Percentage of cells emitting fluorescence from GFP was measured and analyzed.
Cell viability assays
The XTT colorimetric assay (Roche Diagnostics, Indianapolis, IN ) was used to determine cell proliferation and death. Briefly, cells were plated in 96 -well plate at a concentration of 4000 cells/ well. Cells were then exposed and transfected with adenovirus. After incubating cells for 72 hours, the XTT reaction mixture was added, which contains XTT labeling reagent and the electron coupling reagent in a 20:1 ratio. Cell / solution mixtures were then read using the colorimetric plate reader ( Dynatech Labs, Langley, VA ) at a wavelength of 500 nm. Each sample was assayed in triplicate fashion. Data were then analyzed with Microsoft EXCEL software (Microsoft, Redmond, WA ).
Western blot analysis
Total cell lysates were prepared by lysing plated cell monolayers with SDS -PAGE sample buffer. The protein content of the lysates was then determined by BCA protein assay (Pierce, Rockford, IL ). Then, each lane on a SDS polyacrylamide gradient ( 8-12% ) gel was loaded with 5 g of cell lysate and electrophoresed to separate proteins under reducing conditions for BAK, BAX, BCL -XL, and BCL -2. After electrophoresis at 100 V for 2 hours, the proteins were transferred to high -bond Immobilon -P ECL membranes ( Amersham, Piscataway, NJ ). The membranes were then incubated with the primary and secondary antibodies, and developed according to the Amersham ECL protocol.
Flow cytometry analysis
Apoptotic cell death was examined in terms of changes in cell morphology and flow cytometry. Fluorescence -activated cell sorter ( Coulter, Hialeah, FL ) analysis was performed as follows: cells were trypsinized, collected by centrifugation, resuspended in PBS, and fixed in 70% ethanol at 48C for 1 hour. After centrifugation, the cells were washed in PBS and re -suspended in 50 L of TdT buffer with 5 U of TdT enzyme ( Sigma ) and 0.5 nmol biotin -16-dUTP ( Boehringer Mannheim, Indianapolis, IN ). Controls were prepared without TdT enzyme. Cells were incubated at 378C for 1 hour, rinsed in PBS, and re -suspended in 100 L of avidin-FITC in saline-citrate buffer containing 0.1% Triton X -100, 0.1% BSA, 0.5 M NaCl, and 0.06 M sodium citrate. Specimens were incubated in the dark for 30 minutes; the specimens were analyzed with the use of an EPICS Profile II flow cytometer. An analysis region was set based on the negative controls, and the percentage of labeled cells was calculated from this region. Cells in the sub -g1 population area were used to calculate percentage of apoptosis.
DNA extraction, fragmentation assay, terminal deoxynucleotidyltransferase -mediated UTP end labeling ( TUNEL assay ), and Hoechst staining For TUNEL staining, cells were plated on slides following treatment exposure and then fixed in ice -cold paraformaldehyde (Sigma ) for 5 minutes. Next, a methanol /3% H 2 O 2 ( Sigma ) wash was applied for 10 minutes. After incubation, the slides were washed three times with PBS for 2 minutes each time. The slides were then re -incubated at 378C for 2 hours in TdT and Biotin -16 -UTP enzyme mix (Vector Labs, Burlingame, CA ). The slides were then soaked in TB buffer for 10 minutes and washed with PBS for 2 minutes. Slides were then soaked for 30 minutes in diluted blocking serum ( 1 mL horse serum in 3.3 mL PBS /0.1% BSA ) and then washed twice in PBS for 2 minutes each time ). ABC reagent ( 1:50 dilution, 60 L of A and 60 L of B into 3 mL of PBS/ 0.1% BSA ) (Vector Labs ) was used to soak the slides. Slides were rinsed in PBS for 2 minutes for three times. Slides were then exposed to DAB / H 2 O 2 ( Vector Labs) for 1-2 minutes and then washed with running water for 2 minutes. Slides were then counterstained with 0.4% methyl green solution for 10 seconds. Counterstained slides were rinsed again under running water for 2 minutes. Slides were than mounted after an air dry with cytoseal.
For Hoechst staining, cells were plated in chamber slides using a concentration of 5000 cells in 500 L of media. After 24 hours, the cells were exposed to 3 mM SB, followed by vector. After 72 hours, cells were washed with PBS and then fixed with acetone /acetic acid ( 3:1 ). Following fixation, Hoechst nuclear staining solution (0.1 g/ mL ) was added. Nuclei were than examined using the fluorescent microscope ( Nikon Diaphou; Nikon, Melville, NY ). Apoptosis was characterized as cells with large, segmented nuclei.
Isobologram analysis
In order to determine the therapeutic relationship between SB and AdBax, AdBak, and Adp53, two-dimensional isobolograms were constructed using averages from three independent XTT assays for each combination. Three isoeffect curves modes ( I, IIa, IIb ) were created according to the method described previously by Steel and Peckham. 26 The area enclosed by all three lines represents the ''envelope of additivity.'' Experimental data points falling to the left of the envelope signify synergy. When the experimental data point lies to the right of the envelope, it signifies a subadditive relationship.
RESULTS
The combination of SB and PAGT vectors, AdBax and AdBak, increases apoptosis in mesothelioma cell lines
Prior studies have demonstrated the efficacy of adenovirustransducing cells with the bax or bak genes alone to induce apoptosis in tumor cell lines. 21 -23 To determine whether there was induction of apoptosis with a combination of PAGT and SB exposure, varying doses of AdBak or AdBax virus were applied to mesothelioma cells plated on chamber slides, and SB was then added to each set of cells. Using Hoechst staining, the nuclei were examined for apoptotic changes. Cells treated with the PAGT vectors, AdBax and AdBak, alone at 500 vp/ cell ( MOI$10 ) demonstrated minimal evidence of apoptosis. When AdBax 500 vp/cell ( MOI$10) and 3 mM SB were added simultaneously, both the REN and I -45 cell lines demonstrated significant morphologic evidence of apoptosis ( data not shown ).
Increasing the viral titer above this MOI or the SB concentration above 3 mM did not seem to affect the level of apoptosis. In addition, all cells treated with combination therapy demonstrated positive staining (apoptosis ) using the TUNEL assay.
In order to further substantiate induction of apoptosis, flow cytometry for cell cycle analysis following propidium iodide staining was performed in evaluating the sub -g1 population. Cells were treated with 2.5 mM SB following transfection with varying MOI of AdBak or AdBax and FACS analysis was performed at 24 hours. The percentage of cells seen in the sub -g1 population was increased in MOHIUDDIN, CAO, FANG, ET AL: BCL-XL DOWN-REGULATION AND PRO-APOPTOTIC GENE THERAPY combination therapy. In the I -45 cell line, the respective sub -g1 populations following treatment with individual agents AdBax, AdBak, and SB were 28%, 12%, and 3%, respectively, while combination treatments with AdBak /SB and AdBax /SB were 59% and 32%, respectively. In the REN cell line, the respective sub -g1 populations following treatment with individual agents AdBax, AdBak, and SB were 16%, 18%, and 2%, respectively, while combination treatments with AdBak /SB and AdBax / SB were 34% and 48%, respectively (Fig 1, A and B ) .
SB augments the level of PAGT vector ( AdBax and AdBak ) -mediated cell killing
To prove that SB augments PAGT-mediated cell killing, mesothelioma cells were plated in 96-well plates, and transfected at a range of MOI (0 -80 ). Following transfection, SB was added at a dose of 2.5 mM, and viability was assessed utilizing a colorimetric (XTT ) assay ( n= 3 ). Cell killing was greatest at 72 hours. In both cell lines and at all infection ratios, virus -alone cell killing was greatly augmented by the addition of SB. In the I-45 cell line, viabilities at 72 hours following single agent treatment with AdBax, AdBak (MOI 20), and SB were 45%, 51%, and 52%, respectively, while combination treatments with AdBak /SB and AdBax /SB were only 20% and 15%, respectively (Fig 2) . In the REN cell line, viabilities at 72 hours following single agent treatment with AdBax, AdBak ( MOI 20), and SB were 38%, 39%, and 39%, respectively, while combination treatments with AdBak /SB and AdBax / SB were only 5% and 20%, respectively ( Fig 3 ) .
Combination treatment with PAGT vectors, AdBax and AdBak, and SB leads to synergistic cellular killing in REN and I -45
To further characterize the relationship between PAGT and SB, two-dimensional isobolograms were constructed and analyzed for both cell lines utilizing the data from XTT dose -response experiments described combining AdBax / SB and AdBak /SB. For both cell lines, all data points fell to the left of the envelope of additivity, signifying additive, and at some doses, synergistic cellular killing (Fig 4 ) . No points fell to the right of the envelope of additivity, excluding the existence of any subadditivity.
A favorable PAP:AAP ratio of bcl -2 family protein expression is noted following combination treatment
In order to evaluate the expression of the PAP -expressing genes, bax and bak, as well as AAP genes, bcl -2 and bcl-xl, Western blots were performed under reducing conditions following all treatments ( virus alone, butyrate alone, and with combination therapies ). Cells treated with PAGT vectors alone did express a greater amount of their respective proteins, with the other bcl -2 family proteins apparently unaffected. With SB alone, decreased expression of the bclxl protein was noted with no other significant change. Combination therapy in both lines was characterized by increased BAX or BAK and decreased bcl -xl protein expression. Actin expression was unaffected by any treatment ( Fig 5 ) .
SB does not increase adenoviral vector transfection efficiency
Others have suggested that SB increases adenoviral vector transfection efficiency by an uncharacterized mechanism. 27 An increase in efficiency of gene transfer per unit MOI could explain the increases in cellular death and apoptosis noted above by a relatively simple increase in PAP production of bak or bax. The Western blot data presented above do not support this hypothesis as the levels of bak and bax protein do not appear to be augmented with the addition of SB over what is noted by PAGT vector treatment alone. To further elucidate whether or not SB increased adenoviral -mediated transfection efficiency in the REN and I -45 cell lines, cells were transduced with AdGFP (adenovirus vector transferring the green fluorescent protein gene ) at low MOI (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) alone, and following SB exposure. No difference was 
The effect of combination Adp53 and SB treatment is not synergistic
In addition to AdBax and AdBak, the combination of Adp53 and SB was evaluated in the mesothelioma cell lines I-45 and REN. REN ( p53 mutant, and I -45 ( p53 wild type ) demonstrated cell viability rates of 39% and 51%, respectively, following Adp53 treatment alone. The addition of SB did not significantly alter cell viability, and isobologram analysis demonstrated that all data points with dual agent dose -response analysis fell either in the additive or subadditive zones, with no evidence of synergism (Figs 3 -5) .
DISCUSSION
Although classically thought of as a tumor that engenders most, if not all, of its morbidity and mortality from local effects, metastatic disease is now being recognized more commonly in mesothelioma patients, perhaps as a result of more aggressive local treatments. 1, 28, 29 The well-known unresponsiveness of local disease to systemic therapies and the now -increasing appearance of metastatic lesions in patients treated with aggressive local techniques point out clearly the need for novel therapy development for this tumor type, such as artificial induction of programmed cell death or apoptosis. Relatively little is currently known regarding the mechanics and pathways of induction of apoptosis in mesothelioma. It is known that p53 mutations are uncommon in mesothelioma cell lines and tumors, and that wild -type expression of this protein is most common. 30 In an effort to implicate inactivation of an apparently normal wild -type p53 protein, Levresse et al have demonstrated that cell cycle kinetics are altered unfavorably with SV40 large T antigen expression in a mesothelioma cell line when compared to control cells. In addition, these authors demonstrated that forced novel expression of this protein in mesothelioma cells engendered resistance to radiation -induced apoptotic cell death. 31 Unusual agents, such as amphotericin, levostatin, and talc, have been shown to induce apoptosis in mesothelioma cell lines, but no significant elucidation of the subcellular apoptotic pathway( s ) affected has been evaluated using these compounds, and no preconceived effort was made in these studies to directly manipulate them. 32 -34 The bcl -2 family of genes has long been known to be important in the apoptotic pathway of mammalian cells. Alteration of bcl -2 family protein expression balance can either lead to induction of, or resistance to, apoptosis. We previously noted that SB engenders apoptosis in mesothelioma cell lines with a concomitant decrease in the expression of bcl -xl protein, and no change in the expression of PAP BAX or BAK expression. We theorized that overexpression of PAP via PAGT in combination with SB exposure could lead to enhanced cellular death and apoptosis by the simultaneous reduction of AAP (BCL -XL ) and overexpression of PAP (BAX, BAK ) in these cells. The potential solitary importance of bcl -xl in prevention of apoptosis induction in mesothelioma may be illustrated by the fact that expression of another major AAP, BCL -2, is uncommon in these tumors. Soini et al 19 have demonstrated that bcl -2 protein expression was infrequent in human mesothelioma tumor tissue, and that BCL-XL expression, as well as BAX, was uniform. Additional support for an important role for bcl -xl expression in prevention of apoptosis in mesothelioma is provided by antisense studies in nonsmall cell lung carcinoma. In a report evaluating bcl -xl antisense therapy in lung carcinoma cells, it was noted that in those expressing BCL -XL at high levels and little or no BCL -2, apoptosis was engendered. In cell lines with comparable BCL -2 and BCL -XL, no effect was noted. 35 Means to overexpress PAP genes in somatic cells are now readily available. A number of PAGT approaches have recently been evaluated, including adenoviral transfer of the p53 gene both in vitro and in vivo. 24 More recently, the efficacy of use of novel binary systems capable of transferring the bak and bax genes to somatic cells in vitro with resultant apoptosis has been demonstrated. However, although the viral gene transfer systems have now been available for some time, the problems of transfer efficiency and durability of transgene expression using these approaches persist and render monotherapy unlikely. The addition of agents such as SB, which can enhance PAGT effects, may prove beneficial clinically.
Information regarding SB effect on bcl -xl expression in other tumor types has been inconsistent. Bonnotte et al 15 did not note changes in BCL -XL or BCL -2 expression in rat or human colon cancer cells following SB exposure. Alternatively, Wang et al 12 noted significant decreases in bcl-xl expression in two different hepatic carcinoma cell lines following SB exposure, and Litvak et al 11 showed that bcl -2, as well as bcl -xl, mRNA expression was markedly downregulated in human colon cancer cell lines by ribonuclease protection assay. It seems likely that the effects of SB are indeed variable and possibly cell type -specific. Mechanistically, it is interesting that the expression of a gene product is decreased by SB as it is a histone deacetylase inhibitor and would be expected to augment, rather than repress, gene function as it renders DNA structurally more accessible. It would certainly be prudent to consider other more global effects of SB or similar agents on adenoviral transfection or alternatively, efficiency of neogene transcription or translation once cells have been transfected. 26, 36 We did not note a difference in transfection efficiency here, but gene array evaluation and similar studies could be used to determine whether genes known to enhance or decrease adenoviral vector gene product transcription are altered.
In this study, we have taken advantage of the interesting observation that SB down -regulates BCL -XL expression in mesothelioma cell lines to attempt to engender a ''forced therapeutic imbalance'' of bcl -2 family gene expression in mesothelioma cells with adenoviral bax gene transfer. The short half -life of NaB renders it unlikely to be useful in vivo; however, this may be less of a problem in body cavity tumors where local instillation is possible. 18 Other therapeutic interventions, such as molecular approaches ( antisense oligonucleotides, antisense adenoviral vector constructs ) to down -regulation of BCL -XL, could be considered or perhaps derivatives of butyrate with a longer half -life. 37 Additional studies evaluating this type of novel combination approach in animal models of in vivo tumor, as well as mechanistic evaluation of the ability of SB to down -regulate BCL -XL expression, are warranted.
